MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
Mirum Pharmaceuticals, Inc. ( MIRM ) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of +61.29% and +17.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals ( AGIO ) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -10.92% and +34.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. ( MIRM ) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Gains 35% in 3 Months: How Should You Play the Stock?
MIRM jumps 35% in 3 months, driven by soaring Livmarli sales and rising demand for its bile acid products.
EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch
GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.
Why Is Editas ( EDIT ) Up 40% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Mirum Pharmaceuticals ( MIRM ) Down 1.3% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch
GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.
Mirum's Q1 Earnings Beat Estimates, 2025 Revenue View Raised
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
Mirum Pharmaceuticals, Inc. ( MIRM ) Reports Q1 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 23.08% and 13.32%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics ( CYTK ) Reports Q1 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of 3.55% and 26.49%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. ( TNGX ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals ( RYTM ) Moves 5.2% Higher: Will This Strength Last?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Avidity Biosciences ( RNA ) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Mirum Pharmaceuticals ( MIRM ) Down 1.9% Since Last Earnings Report: Can It Rebound?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mirum's Heavy Dependence on Livmarli for Revenues Remains a Woe
MIRM's high reliance on lead drug, Livmarli for revenues remains a worry. Failure to generate sufficient revenues from Livmarli sales is likely to hurt the stock.
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Hemophilia A presentation at American Society of Hematology ( ASH ) 66th Annual Meeting demonstrated sustained Factor VIII ( FVIII ) activity in nonhuman primate ( NHP ) study for more than 16 months ...
MIRM's Q4 Loss Wider Than Expected, Revenues Beat Estimates
Mirum's fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Mirum Pharmaceuticals, Inc. ( MIRM ) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Predict a 26.18% Upside in Mirum Pharmaceuticals ( MIRM ) : Here's What You Should Know
The mean of analysts' price targets for Mirum Pharmaceuticals (MIRM) points to a 26.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
SANA Gears Up to Report Q4 Earnings: What's in the Cards?
On Sana Biotechnology's Q4 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.
SLGL Gears Up to Report Q4 Earnings: Here's What You Should Know
Sol-Gel's fourth-quarter 2024 earnings are likely to have gained from higher licensing revenues from its partners.
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Castle Biosciences' fourth-quarter 2024 earnings are likely to have gained from higher test volume growth of its dermatologic and non-dermatologic tests.
What's in the Cards for Viatris Stock This Q4 Earnings?
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol - Mirum Pharmaceuticals ( NASDAQ:MIRM )
FDA approves Mirum's Ctexli, the first treatment for cerebrotendinous xanthomatosis, a rare genetic disorder affecting fat metabolism. In a trial, Ctexli significantly reduced cholesterol metabolites linked to CTX, but it carries a liver toxicity warning requiring monitoring
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?
On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?
IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
Zoetis Gears Up to Report Q4 Earnings: What's in the Cards?
ZTS' higher companion animal product sales are likely to have driven revenues in fourth-quarter 2024 in both the United States and International segments.
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know
INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.
Mirum Pharmaceuticals ( MIRM ) Upgraded to Buy: What Does It Mean for the Stock?
Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in ...
Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones - Metagenomi ( NASDAQ:MGX )
MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing Approach On Track for One to Two Development Candidate Nominations in 2025 from Wave 1 Ionis ...
Metagenomi Announces New Appointment to its Board of Directors - Metagenomi ( NASDAQ:MGX )
EMERYVILLE, Calif., Jan. 15, 2025 ( GLOBE NEWSWIRE ) -- Metagenomi, Inc.
Axsome ( AXSM ) Moves 11.5% Higher: Will This Strength Last?
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Why Is Mirum Pharmaceuticals ( MIRM ) Down 0.7% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024. Stock rises in pre-market.
Mirum Pharmaceuticals, Inc. ( MIRM ) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of 33.33% and 9.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Intellia Therapeutics, Inc. ( NTLA ) Reports Q3 Loss, Tops Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 2.19% and 7.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Mirum Pharmaceuticals, Inc. ( MIRM ) Report Negative Q3 Earnings? What You Should Know
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is First Trust Small Cap Growth AlphaDEX ETF a Strong ETF Right Now? - First Trust Small Cap Growth AlphaDEX Fund ( NASDAQ:FYC ) , ADMA Biologics ( NASDAQ:ADMA )
Launched on 04/19/2011, the First Trust Small Cap Growth AlphaDEX ETF FYC is a smart beta exchange traded fund offering broad exposure to the Style Box - Small Cap Growth category of the market.
Is First Trust Small Cap Growth AlphaDEX ETF ( FYC ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Should First Trust Small Cap Growth AlphaDEX ETF Be on Your Investing Radar? - First Trust Small Cap Growth AlphaDEX Fund ( NASDAQ:FYC ) , ADMA Biologics ( NASDAQ:ADMA )
Launched on 04/19/2011, the First Trust Small Cap Growth AlphaDEX ETF FYC is a passively managed exchange traded fund designed to provide a broad exposure to the Small Cap Growth segment of the US equity market. The fund is sponsored by First Trust Advisors.
Should First Trust Small Cap Growth AlphaDEX ETF ( FYC ) Be on Your Investing Radar?
Style Box ETF report for ...
Should First Trust Small Cap Core AlphaDEX ETF ( FYX ) Be on Your Investing Radar?
Style Box ETF report for ...
